Results 41 to 50 of about 31,072 (141)
Treatment of alopecia areata partim universalis with efalizumab
, 2006 Alopecia areata (AA) is considered an autoimmune disease targeted at hair follicles with T-lymphocytes playing an important role in the pathogenesis. Treatment of AA, particularly the totalis and universalis subtypes, is often difficult and remains a ...
Kaelin, Ursula +3 more
core +1 more source
Atrichia with papular lesions: A case report
SAGE Open Medical Case Reports, 2020 We present a case of clinically suspected atrichia with papular lesions in an 8-year-old male presenting with alopecia universalis and keratotic papules. We review the literature available on this rare genodermatosis.
Lauren Curry, Kyle Cullingham
doaj +1 more source
Paradoxical Alopecia Areata Induced by IL‐17 and IL‐23 Inhibitors: A Systematic Review
JEADV Clinical Practice, EarlyView.This systematic review identifies consistent clinical patterns of alopecia areata associated with IL‐17 and IL‐23 inhibitors, most frequently involving secukinumab and ustekinumab. Disease severity varied widely, and management often required biologic discontinuation or therapeutic switching.
Isabella Kamholtz +2 more
wiley +1 more source
Acta Dermato-Venereologica, 2018 Treatment of alopecia totalis and alopecia universalis is often challenging and unsatisfactory. Recently, Janus kinase inhibitor has shown promising results.
Jung-Won Shin +6 more
doaj +1 more source
Dermatology and Therapy, 2020 Introduction Cyclosporine is commonly used in treatment for alopecia areata. It can be administered as a monotherapy or in combination with systemic corticosteroids, with various outcomes.
Joanna Nowaczyk +4 more
doaj +1 more source
JEADV Clinical Practice, EarlyView.The SAAD‐41 is a 41‐item scale developed to comprehensively assess Alopecia Areata psychosocial patient‐reported outcomes. Results support scoring the scale at the subdomain level and provisionally at the total‐score level. The total‐score can be calculated as a sum of the 41 SAAD items, with the sum referred to as the SAAD‐41‐Total.
Kristina Gorbatenko‐Roth +5 more
wiley +1 more source
International Journal of Dermatology, EarlyView.Ritlecitinib induced rapid clinical improvement in moderate‐to‐severe alopecia areata in real‐world practice. Early change in SALT at Week 12 strongly discriminated Week‐24 responders, supporting a pragmatic treat‐to‐target checkpoint, alongside improvements in clinician‐reported and patient‐reported outcomes and a favorable safety profile.
Giuseppe Gallo +4 more
wiley +1 more source
Journal of the European Academy of Dermatology and Venereology, EarlyView.This systematic review included 38 studies assessing substance‐related and behavioural addictions in patients with chronic inflammatory skin diseases. Nicotine and alcohol use were the most frequently reported addictive behaviours. Addictions were associated with increased disease severity, impaired treatment outcomes and greater psychosocial burden ...
Enya Müller +5 more
wiley +1 more source
Effective management Alopecia totalis by Ayurveda – A case report
Journal of Ayurveda and Integrative Medicine, 2023 Alopecia areata (AA) is a T-cell-mediated autoimmune illness characterized by intermittent, non-scarring hair loss, Alopecia totalis(AT) is a type of AA characterized by total hair loss on the face and scalp.
Shivanand B. Patil +2 more
doaj +1 more source
Emerging Paediatric Uses of Dupilumab Beyond Approvals
Clinical &Experimental Allergy, Volume 56, Issue 10, Page 1162-1176, October 2026.Dupilumab, through IL‐4Rα blockade, shows promising efficacy beyond approved indications in paediatric diseases driven by T2 inflammation. Emerging evidence—mainly from small studies—supports improvements in disease severity and quality of life, highlighting its potential as a targeted, steroid‐sparing therapy while underscoring the need for ...
Simone Foti Randazzese +11 more
wiley +1 more source